Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 9Neoplasms 7Neoplasm Metastasis 7Carcinoma, Non-Small-Cell Lung 7Triple Negative Breast Neoplasms 6Pancreatic Neoplasms 6Colorectal Neoplasms 5Lymphoma 4Liver Neoplasms 4Lung Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Mesothelioma 2Locally Advanced Rectal Cancer 2Hematologic Diseases 2Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Adenocarcinoma 2Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Solid Tumor, Adult 1

Interventions

Pemetrexed 23Cisplatin 19Nivolumab 8Gemcitabine 7Ipilimumab 6Carboplatin 6pembrolizumab 4Bevacizumab 4tazemetostat 3durvalumab 3Fluorouracil 3Drug Therapy 3spartalizumab 2olaparib 2niraparib 2budigalimab 2belinostat 2anetumab ravtansine 2amatuximab 2Vinorelbine 2Radiotherapy, Intensity-Modulated 2Paclitaxel 2PM 01183 2Oxaliplatin 2Imatinib Mesylate 2Everolimus 2Erlotinib Hydrochloride 2Doxorubicin 2Cyclophosphamide 2venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Mesothelioma × spartalizumab × Clear all
NCT04672434 2024-12-09

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Symphogen A/S

Phase 1 Completed
48 enrolled
GastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Esophageal Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02460224 2022-02-10

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Novartis

Phase 1/2 Completed
490 enrolled 77 charts
DermatologicGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Melanoma, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡